Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
基本信息
- 批准号:10434924
- 负责人:
- 金额:$ 52.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-03-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAffectAllergicAnatomyAntibodiesAntibody FormationAntifungal AgentsAntigensAttentionB-LymphocytesBypassCandidaCandidiasisCell WallCellsCenters for Disease Control and Prevention (U.S.)DataDetectionDevelopmentDiseaseEpithelialEventFoundationsGene MutationGenetic TranscriptionGoalsHealthImmuneImmune responseImmune systemImmunocompromised HostImmunologyIncidenceIndividualInfectionInfectious AgentInflammationInflammatoryInnate Immune ResponseInnate Immune SystemInterferon Type IIInterferonsLectin ReceptorsLifeLigandsLocationLymph Node Subcapsular SinusMediatingMedicalModelingModernizationMycosesOutcomePathway interactionsPatientsPattern recognition receptorPeripheralPersonsPhagocytesPolysaccharidesProcessProductionRoleSentinelSepsisSignal TransductionSolubilityStimulusT-LymphocyteTestingTherapeuticTherapeutic InterventionTimeTissuesVaccinesadaptive immune responseadaptive immunityautoimmune pathogenesiscandidemiadesigndraining lymph nodefungusgenetic signatureglobal healthimprovedinflammatory milieuinnovationinsightmacrophagemicrobialmigrationnovelnovel therapeutic interventionpathogenphysical propertypreventprotein functionrelB proteinresponsetherapeutically effectivetreatment strategy
项目摘要
PROJECT SUMMARY
The dialogue between innate and adaptive branches of the immune system is a central paradigm of modern
immunology and is vital for protection against infections as well as for the pathogenesis of autoimmune, allergic
and inflammatory diseases. According to the current model, innate immune sentinels dispersed throughout
peripheral tissues sense, via their pattern recognition receptors (PRRs), the presence of microbial clues or
endogenous moieties released during an infection, are activated and migrate to the draining lymph node (dLN).
This process enables a transfer of “information” from peripheral tissue to the dLN, where the antigen-dependent
adaptive immune response against the pathogen is initiated. The dLN also hosts an initial antigen-independent,
innate immune response governed by migrating phagocytes that enables expansion of the LN and establishes
a pro-inflammatory milieu. These events are required for the development and polarization of the adaptive
immune response. Here, we focused our attention on the capacity of ligands derived from the cell wall of Candida
(C.) albicans to dictate the LN innate response. Our working hypothesis is that the size and solubility of
stimuli that activate the PRRs affect not only the LN innate response itself, but also the final outcome of
the immune response. Also, that the LN innate response initiated by soluble fungal ligands can be
harnessed to develop a potent and protective adaptive immune response to prevent life-threatening
systemic fungal infections. Our preliminary data demonstrate that the physical form of fungal ligands dictates
the location where the initial immune response takes place, and thereby determines the activation of adaptive
immunity. In particular, we have found that small soluble fungal ligands that are immunosilent in the periphery
and do not cause an inflammation in the tissue, become potent immunogens once they reach the dLN. Also, that
the LN innate response initiated by these ligands completely bypasses the need of phagocyte migration from the
periphery into the dLN and, instead, requires a unique gene signature that is characterized by the production of
interferons and that is driven by the activation of the noncanonical NFkB transcription factor RelB in subcapsular
sinus macrophages. Notably, Dectins are required for this process but CARD9, the key signaling adaptor
downstream of Dectins, is largely dispensable. Plus, the initial innate response to the dLN instructs a potent
type 1 adaptive immunity and allows the production of antibodies directed against the most external layer of the
fungal cell wall. Fungal diseases are a global health problem and Candida species are the most common cause
of invasive fungal infections. We propose to unravel how physical properties of the PAMPs can be harnessed as
a therapeutic intervention against systemic fungal infections that are a major medical problem in the US. We
anticipate that identifying new features of the immune response that is anatomically restricted to the LN will help
with the design of an improved vaccine against poorly controlled pathogens.
项目总结
免疫系统的先天分支和适应性分支之间的对话是现代
免疫学,对预防感染以及自身免疫性过敏性疾病的发病机制至关重要。
和炎症性疾病。根据目前的模型,先天免疫哨兵分散在
外周组织通过其模式识别受体(PRR)感知微生物线索或
在感染期间释放的内源性部分被激活并迁移到引流淋巴结(DLN)。
这一过程使“信息”从周围组织转移到DLN,在DLN中依赖于抗原
启动针对病原体的适应性免疫反应。DLN还拥有一种最初的抗原非依赖性、
由迁徙的吞噬细胞控制的先天免疫反应,使LN扩张并建立
一个有利于发炎的环境。这些事件是适应性发展和两极分化所必需的
免疫反应。在这里,我们将注意力集中在念珠菌细胞壁衍生的配体的能力上。
(C.)白念珠菌决定了LN的先天反应。我们的工作假设是,大小和溶解度
激活PRRs的刺激不仅影响LN固有反应本身,还影响LN的最终结果
免疫反应。此外,由可溶性真菌配体启动的LN先天反应可以是
被利用来开发有效的保护性适应性免疫反应,以防止危及生命
系统性真菌感染。我们的初步数据表明,真菌配体的物理形式决定了
初始免疫反应发生的位置,从而决定适应性免疫的激活
豁免权。特别是,我们发现在外周免疫沉默的小的可溶性真菌配体
并且不会在组织中引起炎症,一旦到达DLN就会成为有效的免疫原。还有,就是
由这些配体启动的层粘连蛋白先天反应完全绕过了吞噬细胞从
而是需要一种独特的基因签名,其特征是产生
干扰素,这是由被膜下非规范转录因子RelB激活所驱动的
鼻窦巨噬细胞。值得注意的是,这个过程需要Dectins,但关键的信令适配器CARD9
在迪金斯的下游,基本上是可有可无的。此外,对DLN的最初先天反应指示了一种强有力的
1型获得性免疫,并允许产生针对病毒最外层的抗体
真菌细胞壁。真菌疾病是一个全球性的健康问题,而念珠菌是最常见的原因
侵袭性真菌感染。我们建议解开如何利用PAMP的物理性质作为
针对系统性真菌感染的治疗性干预,这是美国的一个主要医疗问题。我们
预计识别解剖学上局限于LN的免疫反应的新特征将有所帮助
设计了一种针对控制不佳的病原体的改进疫苗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ivan Zanoni其他文献
Ivan Zanoni的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ivan Zanoni', 18)}}的其他基金
Macrophage immunometabolism controls septic shock
巨噬细胞免疫代谢控制感染性休克
- 批准号:
10658162 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans
通过调节真菌甘露聚糖的物理特性开发新型佐剂策略
- 批准号:
10338399 - 财政年份:2021
- 资助金额:
$ 52.25万 - 项目类别:
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans
通过调节真菌甘露聚糖的物理特性开发新型佐剂策略
- 批准号:
10490881 - 财政年份:2021
- 资助金额:
$ 52.25万 - 项目类别:
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans
通过调节真菌甘露聚糖的物理特性开发新型佐剂策略
- 批准号:
10687182 - 财政年份:2021
- 资助金额:
$ 52.25万 - 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
- 批准号:
10293993 - 财政年份:2016
- 资助金额:
$ 52.25万 - 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
- 批准号:
10641775 - 财政年份:2016
- 资助金额:
$ 52.25万 - 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
- 批准号:
9122779 - 财政年份:2016
- 资助金额:
$ 52.25万 - 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
- 批准号:
9232989 - 财政年份:2016
- 资助金额:
$ 52.25万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别: